Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Genome-wide chromatin accessibility changes over time in cultured primary human monocytes due to DMOG treatment

ABSTRACT: Genome-wide chromatin accessibility changes over time in cultured primary human monocytes due to DMOG treatment

PROVIDER: PRJNA698950 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Genome-wide chromatin accessibility changes over time in cultured primary human monocytes due to DMOG treatment

Project description:ATAC sequencing of primary human monocytes cultured with and without hypoxia-mimetic agent DMOG (Dimethyloxalylglycine). Monocytes isolated from PBMCs of 7 healthy donors were cultured with and without DMOG for 24hrs and harvested at 0, 2, 10 or 24hrs for RNA sequencing. DMOG suppresses HIF Prolyl hydroxylase (HIF-PH) activity by acting as a small molecule competitive inhibitor. HIF-PH inhibition leads to increase in endogenous HIF protein levels and mimics aspects of hypoxia. This ATAC-seq study allows analysis of genome-wide changes to chromatin accessibility due to DMOG treatment.

2022-04-13 | GSE165997 | GEO

Transcriptome-wide expression changes over time in cultured primary human monocytes due to DMOG treatment

Project description:RNA sequencing of primary human monocytes cultured with and without hypoxia-mimetic agent DMOG (Dimethyloxalylglycine). Monocytes isolated from PBMCs of 7 healthy donors were cultured with and without DMOG for 24hrs and harvested at 0, 2, 10 or 24hrs for RNA sequencing. DMOG suppresses HIF Prolyl hydroxylase (HIF-PH) activity by acting as a small molecule competitive inhibitor. HIF-PH inhibition leads to increase in endogenous HIF protein levels and mimics aspects of hypoxia. This RNA-seq study allows analysis of transciptome-wide expression pattern changes over time due to DMOG treatment.

2022-04-13 | GSE165998 | GEO

Transcriptome-wide expression changes over time in cultured primary human monocytes due to DMOG treatment

Project description:Transcriptome-wide expression changes over time in cultured primary human monocytes due to DMOG treatment

| PRJNA698949 | ENA

Genome-wide chromatin accessibility and transcriptome-wide expression changes over time in cultured primary human monocytes due to DMOG treatment

Project description:Genome-wide chromatin accessibility and transcriptome-wide expression changes over time in cultured primary human monocytes due to DMOG treatment

| PRJNA698944 | ENA

Next-Generation Standard RNA-Sequencing Analysis of human monocytes stimulated by HMGB1 with or without DMOG

Project description:We report the application of standard RNA-sequencing technology for high-throughput profiling of differential gene expression in mammalian cells. This study aims to compare differential gene expression in human monocytes in the absence or presence of HMGB1 and DMOG exposure would mimic hypoxia. Human monocytes (five million cells) from a healthy donor were divided into four groups in triplicate (control, DMOG, HMGB1 or HMGB1_DMOG). RNA isolation, RNA integrity check, library preparation and ~350M raw paired-end reads per lane (Illumina HISeq. 2x150 bp sequencing) were conducted at GENEWIZ, LLC. We find that increased TNF signaling induced by HMGB1 and enhanced when DMOG was present, and reduced IFN signaling in DMOG in unstimulated and HMGB1-stimulated conditions. We conclude that RNA-seq based UP and DOWN regulated genes/pathways characterization would confirm our results and expedite genetic network analyses.

2021-06-03 | GSE162834 | GEO

Genome-wide chromatin accessibility and transcriptome-wide expression changes over time in cultured primary human monocytes due to DMOG treatment

Project description:This SuperSeries is composed of the SubSeries listed below.

2022-04-13 | GSE165999 | GEO

Expression data from the hepatic stellate cell line LX-2 after treatment with DMOG and from the liver sinusoidal endothelial cell line TRP3 after incubation with conditioned medium of DMOG-treated LX-2

Project description:Expression data from the hepatic stellate cell line LX-2 after treatment with the prolylhydroxylase inhibitor dimethyloxalylglycine (DMOG) and from the liver sinusoidal endothelial cell line TRP3 after incubation with conditioned medium of DMOG-treated LX-2 Prolyl-hydroxylase inhibitors such as dimethyloxalylglycine (DMOG) stabilize HIF-1α, thereby chemically inducing hypoxia, which also accelerates liver volume increase when given with portal rerouting. We used microarrays to clarify the cellular crosstalk of the different cell types in accelerated liver regeneration by examining the role of hepatic stellate cells (HSC) and liver sinusoidal endothelial cells (LSEC).

2020-03-23 | GSE131168 | GEO

Next-Generation Standard RNA-Sequencing Analysis of human monocytes stimulated by HMGB1 with or without DMOG

Project description:Next-Generation Standard RNA-Sequencing Analysis of human monocytes stimulated by HMGB1 with or without DMOG

| PRJNA683227 | ENA

Genome-wide chromatin accessibility changes in cultured primary human monocytes cultured at low density and high density.

Project description:ATAC sequencing of primary human monocytes cultured at low and high density. Monocytes isolated from PBMCs of 3 healthy donors were cultured at low density (1 x 10^6 cells/mL) or at high density (1 x10^7 cells/mL) for 24hrs and harvested for ATAC sequencing. Protein expression of FcgR2b is higher on monocytes in high density conditions compared to low density conditions, where expression is negligble. This study provides information on genome-wide chromatin accessibility changes that occur in high density culture in order to study associations with FcgR2b expression.

2022-04-13 | GSE166100 | GEO

Hypoxia and dimethyloxalylglycine (DMOG) downregulates tryptophan-2,3-dioxygenase (TDO2) expression in GBM cells

Project description:The tryptophan degrading enzyme TDO2 is downregulated upon HIF1alpha stabilization by exposure to both hypoxia as well as chemical hypoxia mimetics such as DMOG in glioblastoma cell line A172.

2019-12-29 | GSE138535 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data